Human mortality from canine rabies is estimated by World Health Organization (WHO) to be 55.000 deaths per year. Limited supply hampers the accessibility of appropriate life saving treatment, particularly in endemic areas Anti-rabies immunoglobulin is currently used in combination with rabies vaccine to protect humans from lethal rabies. For cost and safety reasons, replacement of the human and equine polyclonal immunoglobulin is advocated and the use of rabies-specific monoclonal antibodies (mAbs) is advocated.
展开▼
